Pfizer COVID-19 vaccine update: Final results show it’s now 95% effective

{ object.primary_image.title }}

But don’t let your COVID-19 guard down yet. There’s still a long way to go before most people will receive the vaccine. Earlier this month, pharmaceutical giant Pfizer gave us some of the best news all year : Their COVID-19 vaccine was found to be effective in more than 90% of the people who received it. However, that news was preliminary, and the company was waiting on further results to see if the efficacy rating held. Read Full Story

Read Full Article on Fast Company

Moderna’s COVID-19 vaccine: 5 things you need to know

{ object.primary_image.title }}

Early signs are encouraging, but we need to let the science take its time and not get our hopes too high yet. Last week the world got a big dose of promising news: Pharma giant Pfizer announced early results showing its COVID-19 vaccine was effective in more than 90% of the people who received it. This week is also getting off to a good start. American biotech giant Moderna has now announced that its own COVID-19 vaccine is effective in 94.5% of the people who received it, reports The Wall Street Journal . Here’s what you need to know: Read Full Story

More

Pfizer’s CEO: 3 key decisions helped it develop a COVID-19 vaccine in record time

{ object.primary_image.title }}

In an interview with Fast Company Editor-in-Chief Stephanie Mehta, Pfizer CEO Albert Bourla credited quick decision-making, trust in science, and artificial intelligence software for his company’s ability to create a highly effective COVID-19 vaccine in record time. Last year, Pfizer was one of several pharmaceutical companies to take on an incredible challenge: make a life-saving vaccine in a fraction of the time it usually takes to do so. Over the course of 2020, Pfizer and others tested vaccine candidates as hundreds of thousands of people died from COVID-19. Pfizer’s success at creating a vaccine with 95% efficacy in record time has landed it, along with its partner BioNTech and fellow vaccine maker Moderna, atop Fast Company ‘s Most Innovative Companies list for 2021 . Read Full Story

More

AstraZeneca’s COVID-19 vaccine has 79% efficacy in new U.S.-based trial

{ object.primary_image.title }}

The latest Phase III trial encompassed 32,000 participants, 21,583 of those receiving at least one dose of the AstraZeneca vaccine. The beleaguered AstraZeneca COVID-19 vaccine got a big shot in the arm, so to speak, today with results of the latest clinical trial which showed the vaccine is 79% effective against the virus. Previous studies pegged the AstraZeneca vaccine with an efficacy of 67%. Best of all, the latest trials reconfirmed what earlier ones did: AstraZeneca’s vaccine is 100% effective at preventing severe disease and hospitalization from COVID-19. Read Full Story

More

Subscribe to our newsletter

Join our newsletter and never miss out trending marketing news.

HitcountVariables(pk=11592, ajax_url='/api/hit/ajax/', hits='3')